| IPO Company Profile © ipodata.com |
| Message Board | Quote | Chart | News | SEC Filings | Peer IPO Companies |
| Tularik, Inc. |
| Two Corporate Drive, South San Francisco, CA 94080 * (650) 825-7000 |
| Business Description | The company is engaged in the discovery and development of a broad range of novel and superior orally available drugs based on gene regulation. |
| Offering Information Company has | |||
| Trading As | TLRK (NASNTL) | Industry | Service (SIC 8731) |
| Type of Stock Offered | Common Shares | Filing Date | 10/15/99 |
| Domestic Shares Offered | 6,950,000 | Offer Date | 12/9/99 |
| Foreign Shares Offered | 0 | Filing Range | $11.00 - $13.00 |
| Company Shares | 6,950,000 | Offer Price | $14.00 |
| Selling Shrhldrs Shares | 0 | Gross Spread | $0.980 |
| Gross Proceeds | $97,300,000 | Selling | $0.580 |
| Expenses | - - | Reallowance | $0.100 |
| Post-IPO Shares | 41,521,400 | Employees | - - |
| Primary Underwriting Group | ||
| Underwriter Name | Participation | Underwriter Phone |
| Lehman Brothers Incorporated | Lead Manager | (212) 526-8100 |
| Hambrecht & Quist Incorporated | Co-manager | (415) 439-3626 |
| J.P. Morgan & Co. | Co-manager | (212) 648-0517 |
| Warburg Dillon Read LLC | Co-manager | (203) 719-4290 |
| Income Statement and Cash Flow Summary | |||||||
| Prior Audited Income |
Latest Unaudited Income | ||||||
| Full Year Audited Figures | 6 Months Ending | ||||||
| Figures in U.S. millions except per share data | 12/31/94 | 12/31/95 | 12/31/96 | 12/31/97 | 12/31/98 | 6/30/98 | 6/30/99 |
| Revenues | 5.618 | 11.124 | 15.297 | 20.009 | 21.362 | 8.962 | 11.993 |
| Income from Oper. | - | - | - | - | - | - | - |
| Net Income | -5.898 | -3.607 | -5.480 | -25.374 | -10.539 | -6.183 | -9.879 |
| E.P.S | - | - | - | - | -0.310 | - | -0.290 |
| Revenue Growth (%) | 98.01 | 37.51 | 30.80 | 6.762 | 33.82 | ||
| Net Income Growth (%) | - | - | - | - | - | ||
| Oper. Profit Margin (%) | - | - | - | - | - | - | - |
| Net Profit Margin (%) | - | - | - | - | - | - | - |
| Cash Flow - Oper. | -0.72 | -5.09 | -12.13 | ||||
| Cash Flow - Inv. | -23.17 | -13.19 | -14.73 | ||||
| Cash Flow - Fin. | 2.75 | 1.26 | 9.81 | ||||
| Balance Sheet Summary and Financial Ratios | |||||
| Balance sheet as of: 6/30/99 | Financial Ratios | ||||
| Total Assets | 133.93 | Current Assets | 113.65 | Current Ratio | 6.10 |
| Total Liab. | 30.59 | Current Liab. | 18.64 | Debt Ratio | 22.84% |
| Total Equity | 103.34 | Working Cap. | 95.01 | Debt to Equity Ratio | 0.30 |
| Cash | 36.34 | Return on Assets | - | ||
| Use Of Proceeds |
The proceeds from the proposed offering will be used for research and development and general corporate purposes. |
| Legal Counsel Registrar Auditor | |
| Issuer's Law Firm | Cooley Godward Castro Huddleson & Tatum |
| Bank's Law Firm | Latham & Watkins |
| Registrar/Transfer Agent | Norwest Bank of Minnesota |
| Auditor | Ernst & Young |
| Send us feedback if you would like to request that we hyperlink a firm on this page | |